What markers track sex hormone-binding globulin?

Sex hormone-binding globulin (SHBG) is a 373-amino-acid secreted glycoprotein of the steroid-binding protein family, encoded by the SHBG gene on chromosome 17p13.1. It circulates as a homodimer and binds testosterone and estradiol with high affinity, regulating their free fractions. In the research literature, SHBG is measured as a serum or plasma analyte, often alongside total testosterone, free androgen index, and insulin. The work described below centres on the insulin–SHBG axis and its intersection with hepatic and reproductive endpoints.

SHBG synthesis occurs primarily in hepatocytes, and its regulation is studied in the context of insulin signalling and androgen exposure. The pathway most often invoked is the insulin receptor–mediated suppression of hepatic SHBG transcription, with downstream effects on circulating androgen bioavailability.

Research Studies

Vildagliptin and SHBG in polycystic ovary syndrome

A registered clinical trial compares vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, with metformin in patients with polycystic ovary syndrome (PCOS) [1]. The evidence block states that hyperinsulinemia can enhance ovarian androgen production and reduce hepatic SHBG synthesis, thereby aggravating hyperandrogenism and reproductive abnormalities [1]. The trial is designed to assess whether DPP-4 inhibition, which enhances endogenous incretin activity, may improve insulin sensitivity and glucose homeostasis, and emerging evidence suggests it may also influence body weight, androgen excess, and inflammation [1]. SHBG is not listed as a primary outcome in the available excerpt, but the mechanistic rationale links insulin-lowering interventions to hepatic SHBG output.

Metformin and SHBG in PCOS

Metformin is the active comparator in the same trial [1]. Because metformin is an insulin-sensitizing agent, its use in PCOS is studied in relation to the same insulin–SHBG axis: lower circulating insulin is expected to disinhibit hepatic SHBG production. The evidence block does not provide SHBG values for either arm, so no quantitative comparison can be made here.

Insulin and hepatic SHBG synthesis in PCOS

The evidence block explicitly states that hyperinsulinemia reduces hepatic SHBG synthesis [1]. This is a mechanistic statement about the liver as the source of circulating SHBG and about insulin as a suppressor of its production. The population in which this was observed is patients with PCOS, as described in the trial record [1]. No animal-only or in vitro data are cited in the evidence block for this specific claim.

Androgen excess and SHBG in PCOS

PCOS is characterized by hyperandrogenism, ovulatory dysfunction, and polycystic ovarian morphology [1]. SHBG is the binding protein that determines the free fraction of androgens; when hepatic SHBG synthesis falls, the free androgen index rises. The evidence block frames this as a consequence of hyperinsulinemia rather than as an independent driver [1]. The population is again patients with PCOS.

DPP-4 inhibition and metabolic markers in PCOS

Vildagliptin is described as enhancing endogenous incretin activity and potentially improving insulin sensitivity and glucose homeostasis [1]. The same source notes that DPP-4 inhibition may influence body weight, androgen excess, and inflammation [1]. These are candidate markers that could be tracked alongside SHBG in interventional studies, but the evidence block does not report measured SHBG changes.

Hepatic steatosis and SHBG in adolescent girls with PCOS

A separate prospective observational study, COMPASS-pedPCOS, evaluates whether PCOS contributes to hepatic steatosis in adolescent girls independently of adiposity [2]. The study enrols 150 girls aged 10–18 years into three groups of 50: girls with PCOS and obesity, age- and body mass index-matched girls with obesity but without PCOS, and healthy normal-weight girls [2]. Each participant undergoes anthropometry, clinical and biochemical phenotyping, transient elastography with controlled attenuation parameter, two-dimensional shear wave elastography, and a single venous blood sample [2]. Because SHBG is hepatically derived, this study design provides a model in which liver fat and SHBG could be examined together, though the evidence block does not list SHBG among the named assessments.

Adiposity and SHBG in adolescent girls

The COMPASS-pedPCOS design explicitly matches groups by age and body mass index to isolate PCOS status from adiposity [2]. This matters for SHBG research because adiposity and insulin resistance are both associated with lower SHBG, and matching allows the independent contribution of PCOS to be assessed. The population is adolescent girls aged 10–18 years [2].

Biomarker panels and SHBG in PCOS-associated liver steatosis

The COMPASS-pedPCOS study is described as a biomarker panel study for PCOS-associated liver steatosis [2]. It combines imaging-based liver fat measures with a single venous blood sample [2]. SHBG is not named in the excerpt, but it is a plausible component of a hepatic–metabolic biomarker panel given its hepatic origin and its inverse relationship with insulin. No panel composition is provided in the evidence block.

Comparing study designs for SHBG-related markers

The table summarises the two evidence sources. Neither source reports measured SHBG concentrations, so the table lists only the markers and mechanisms that the evidence block associates with SHBG biology.

If you are reading this for personal health reasons

The materials described here are sold for laboratory research use only. We do not provide dosing, medical guidance, or personal health advice. Anyone considering a compound for themselves should speak to a licensed clinician.

Sources

• [1] Efficacy of Vildagliptin Versus Metformin in Patients With Polycystic Ovary Syndrome — ClinicalTrials.gov
• [2] Biomarker Panel for PCOS-Associated Liver Steatosis in Adolescent Girls (COMPASS-pedPCOS) — ClinicalTrials.gov